Skip to main content

Table 2 Evolution of rhinitis over a 14-day course of antihistamines

From: Evaluation of patients’ expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index – the benefica study

 

N = 3089

Baseline

End of study

Discomfort (cm)

7.2 ± 1.4

3.1 ± 1.5*

MiniRQLQ

46.3 ± 14.5

14.7 ± 11.6*

  Activities

11.0 ± 3.5

3.9 ± 3.0*

  Practical problems

8.0 ± 2.2

2.7 ± 2.1*

  Nasal symptoms

12.3 ± 3.3

4.0 ± 3.0*

  Ocular symptoms

8.7 ± 4.7

2.4 ± 2.8*

  Other problems

6.3 ± 4.3

1.8 ± 2.5*

Somnolence score

2.6 ± 1.6

0.8 ± 1.1*

  1. Results are expressed as mean ± SD for continuous variables and frequency (percentage in documented data) for categorical variables. Discomfort is self-evaluated by the patient on a 10-cm visual analog scale; *p < 0.0001 between baseline and end of study.